Literature DB >> 33652960

Novel Targeted Therapies for Advanced Cholangiocarcinoma.

Alessandro Rizzo1,2, Giovanni Brandi1,2.   

Abstract

Cholangiocarcinoma (CCA) includes a group of rare and aggressive hepatobiliary malignancies, including extrahepatic cholangiocarcinoma (eCCA) and intrahepatic cholangiocarcinoma (iCCA), with the former further subdivided into distal (dCCA) and perihilar cholangiocarcinoma (pCCA) [...].

Entities:  

Year:  2021        PMID： 33652960      PMCID： PMC7996824          DOI： 10.3390/medicina57030212

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN： 1010-660X            Impact factor:   2.430


  30 in total

1.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Authors:  Lipika Goyal; Lei Shi; Leah Y Liu; Ferran Fece de la Cruz; Jochen K Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W S Ng; Phuong Vu; Krushna C Patra; Supriya K Saha; Raul N Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A Shahzade; Ipsita Dey-Guha; Isobel J Fetter; Islam Baiev; Emily E Van Seventer; Janet E Murphy; Cristina R Ferrone; Kenneth K Tanabe; Vikram Deshpande; James J Harding; Rona Yaeger; Robin K Kelley; Alberto Bardelli; A John Iafrate; William C Hahn; Cyril H Benes; David T Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X Zhu; Ryan B Corcoran; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2019-05-20       Impact factor: 39.397

2.  The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.

Authors:  Qurat Ul Ain Riaz Sipra; Rachna Shroff
Journal:  Expert Opin Investig Drugs       Date:  2020-11-23       Impact factor: 6.206

3.  Immunotherapies in clinical development for biliary tract cancer.

Authors:  Arndt Vogel; Melanie Bathon; Anna Saborowski
Journal:  Expert Opin Investig Drugs       Date:  2020-12-31       Impact factor: 6.206

Review 4.  Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.

Authors:  Angela Lamarca; Jorge Barriuso; Mairéad G McNamara; Juan W Valle
Journal:  J Hepatol       Date:  2020-03-12       Impact factor: 25.083

5.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

6.  Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.

Authors:  Gehan Botrus; Puneet Raman; Thomas Oliver; Tanios Bekaii-Saab
Journal:  Expert Opin Investig Drugs       Date:  2021-01-04       Impact factor: 6.206

Review 7.  BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.

Authors:  Alessandro Rizzo; Giovanni Brandi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-18       Impact factor: 3.869

8.  Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Authors:  Vincenzo Mazzaferro; Bassel F El-Rayes; Michele Droz Dit Busset; Christian Cotsoglou; William P Harris; Nevena Damjanov; Gianluca Masi; Lorenza Rimassa; Nicola Personeni; Fadi Braiteh; Vittorina Zagonel; Kyriakos P Papadopoulos; Terence Hall; Yunxia Wang; Brian Schwartz; Julia Kazakin; Sherrie Bhoori; Filippo de Braud; Walid L Shaib
Journal:  Br J Cancer       Date:  2018-11-13       Impact factor: 7.640

Review 9.  PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Giovanni Brandi
Journal:  Cancers (Basel)       Date:  2021-02-01       Impact factor: 6.639

Review 10.  Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Giovanni Brandi
Journal:  Expert Opin Investig Drugs       Date:  2020-10-25       Impact factor: 6.206
View more
  2 in total

Review 1.  Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.

Authors:  Alessandro Rizzo
Journal:  Medicina (Kaunas)       Date:  2021-05-08       Impact factor: 2.430

2.  Cystic Duct Carcinoma: A New Classification System and the Clinicopathological Features of 62 Patients.

Authors:  Lingxi Nan; Changcheng Wang; Yajie Dai; Jie Wang; Xiaobo Bo; Shulong Zhang; Dexiang Zhang; Houbao Liu; Yueqi Wang
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.